Columns

Traditional markets have grown crowded with acceptable treatments for large patient populations, which can limit access for drugs in development for these therapeutic areas. Rather than taking a head-on approach to an entire market and the competition therein, it may be advantageous for manufacturers initially to consider more targeted opportunities.
The articles in this issue discuss practical considerations for achieving goals of improving patient care.
Authors discuss how the use of formulary exclusion lists is expanding and what this trend means for different patient populations and payer organizations. 
Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD and Scott Guerin, PhD discuss how the the upcoming presidential election might impact clinical pathways.
In this issue, several articles discuss ways in which clinical pathways can be more personalized and patient-centered. 
Authors discuss how recent advancements in health care systems have affected physicians' ability to acheive the Triple Aim.
Authors explore the use of prostate-specific antigen screening and urge stakeholders to clarify how screening can be more usefully applied for prostate cancer.
The latest issue of Journal of Clinical Pathways looks at the importance of incorporating the patient perspective in health care decision-making.
In this article, authors look at value tools now available that are increasingly being utilized by payers in oncology to improve care delivery and better manage costs. 
The quality of life measure is becoming more important in determining the effectiveness of different treatment options and the development of clinical pathways.